What are the latest medical updates?

Latest Medical Updates in Clinical Practice Guidelines (2024-2026)

The most significant recent updates span acute stroke management, cardiovascular risk assessment, pulmonary embolism treatment, and infectious disease management, with paradigm shifts in thrombolytic eligibility, lipid-lowering strategies, and PE severity classification.

Acute Ischemic Stroke Management (2026)

The American Heart Association/American Stroke Association released comprehensive updates to acute ischemic stroke management in 2026, representing the first major revision since 2018 1.

Key Changes in Thrombolytic Therapy

• Modified contraindication criteria for thrombolytic therapy now allow treatment in previously excluded populations 1
• Expanded eligibility criteria for endovascular thrombectomy based on new imaging and time window evidence 1
• Updated thrombolytic agent selection guidance reflecting comparative effectiveness data 1

Critical Management Updates

• Hyperglycemia management protocols have been refined with specific glucose targets during acute stroke care 1
• Dysphagia screening and management recommendations now include standardized assessment tools 1
• Pediatric stroke considerations are now explicitly addressed, filling a previous gap 1

Cardiovascular Risk Assessment and Lipid Management (2025)

The European Society of Cardiology/European Atherosclerosis Society published focused updates to dyslipidemia guidelines in 2025, fundamentally changing risk stratification and treatment approaches 2.

Revolutionary Risk Assessment Changes

• SCORE2 and SCORE2-OP algorithms replace previous models, now predicting both fatal and non-fatal cardiovascular events up to age 89 2
• Risk assessment for women and younger patients has been corrected, addressing historical underestimation 2
• Universal lipoprotein(a) testing is now recommended at least once in adulthood for all patients 2

Aggressive LDL-Cholesterol Lowering Strategy

• Immediate combination therapy (high-intensity statin plus ezetimibe) is now recommended for most acute coronary syndrome patients, abandoning the sequential approach 2
• Expanded pharmacological arsenal includes bempedoic acid, evinacumab, and inclisiran for LDL-cholesterol lowering 2
• Icosapent ethyl (not EPA/DHA mixtures) is specified for triglyceride management 2

Common Pitfall: The guidelines acknowledge that real-world implementation lags significantly behind evidence generation, with an average 17-year delay in practice change 2.

Pulmonary Embolism Management (2026)

The 2026 multi-society guideline introduces a new classification system that fundamentally changes PE management 3.

AHA/ACC Acute Pulmonary Embolism Clinical Categories

• New severity classification system enhances precision in prognosis assessment and therapeutic decision-making 3
• Risk-stratified treatment algorithms now guide pharmacological and interventional therapy selection 3
• Adjunctive cardiovascular testing recommendations specify when echocardiography, CT, and biomarkers should be obtained 3

Management Strategies

• Advanced interventional therapies have expanded indications based on PE severity category 3
• Post-acute phase management includes structured follow-up protocols through clinical recovery 3
• In-hospital support strategies are tailored to hemodynamic status and comorbidities 3

Thoracic Aortic Disease Management (2026)

The European Society for Vascular Surgery issued 129 recommendations across thoracic aortic pathologies 4.

Major Clinical Areas Addressed

• Acute thoracic aortic syndrome management protocols have been updated with specific intervention thresholds 4
• Chronic type B aortic dissection surveillance and treatment timing recommendations 4
• Blunt thoracic aortic injury management in trauma settings 4

Special Considerations

• Spinal cord ischemia prevention strategies during thoracoabdominal aortic repair 4
• Left subclavian artery revascularization indications and techniques 4
• Pregnancy-specific considerations for aortic disease management 4

Sepsis Management (2025)

German S3 guidelines updated sepsis management with 29 new and 16 revised recommendations 5.

Core Updates

• Early individualized treatment protocols emphasize rapid pathogen identification and targeted antimicrobial therapy 5
• Structured follow-up care after hospital discharge is now a guideline component 5
• Patient-centered comprehensive care extends beyond acute treatment phase 5

Critical Point: Despite advances in early detection and intensive care, sepsis remains life-threatening, requiring immediate diagnosis and treatment initiation 5.

HIV Treatment and Prevention (2024)

The International Antiviral Society-USA Panel updated recommendations for antiretroviral therapy 6.

Treatment Recommendations

• Integrase strand transfer inhibitors (bictegravir or dolutegravir) with 2 nucleoside reverse transcriptase inhibitors remain first-line for most patients 6
• Long-acting injectable therapy is now available for patients preferring alternatives to daily oral medications 6
• Pregnancy-specific regimens and management of active opportunistic diseases are addressed 6

Prevention Strategies

• Oral and injectable long-acting medications are effective for pre-exposure prophylaxis 6
• Doxycycline post-exposure prophylaxis for sexually transmitted infection prevention is recommended 6
• Substance use disorder management strategies are integrated into HIV care 6

COVID-19 Management in Assisted-Living Settings (2025)

Updated treatment protocols prioritize rapid antiviral initiation and drug interaction management 7.

First-Line Antiviral Therapy

• Nirmatrelvir/ritonavir 300 mg/100 mg orally every 12 hours for 5 days is first-line for high-risk patients based on high-certainty evidence of hospitalization reduction 7
• Renal dose adjustment to nirmatrelvir 150 mg/ritonavir 100 mg every 12 hours is required for eGFR 30-59 mL/min 7
• Liverpool COVID-19 Drug Interaction Tool must be consulted before prescribing due to ritonavir's potent CYP3A4 inhibition 7

Alternative Options

• Remdesivir 200 mg IV on Day 1, then 100 mg IV daily for 2 days may provide larger hospitalization reduction than molnupiravir 7
• Molnupiravir is conditionally recommended only when nirmatrelvir/ritonavir and remdesivir are unavailable, and is contraindicated in patients of childbearing potential 7

Medications to Avoid

• Hydroxychloroquine, lopinavir-ritonavir, and ivermectin are not recommended due to lack of benefit or increased mortality 7

Overactive Bladder Management (2019)

The AUA/SUFU guideline amendment introduced combination therapy recommendations 6.

Treatment Algorithm

• Behavioral treatments may be combined with pharmacologic management from treatment initiation 6
• Combination therapy with an anti-muscarinic and β3-adrenoceptor agonist is recommended for patients refractory to monotherapy 6
• Advanced therapies (intradetrusor onabotulinumtoxin, peripheral tibial nerve stimulation, or sacral neuromodulation) are reserved for patients failing pharmacologic management 6

Castration-Resistant Prostate Cancer (2018)

The AUA guideline amendment addressed non-metastatic CRPC management 6.

Treatment Landscape

• Six FDA-approved agents demonstrating survival benefit are now available beyond docetaxel: enzalutamide, abiraterone, apalutamide, sipuleucel-T, and radium-223 6
• Non-metastatic CRPC now has specific treatment recommendations to delay progression to metastatic disease 6
• Median survival for metastatic CRPC has improved from less than 2 years to 5 or more years with novel agents 6